Search

Displaying results 3201 - 3210 of 5302 in total
  1. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287].

  2. Drug

    Penbutolol

    go.drugbank.com/drugs/DB01359
    ApprovedInvestigationalWithdrawn

    Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug.

  3. Drug

    Magnesium cation

    go.drugbank.com/drugs/DB01378
    ApprovedInvestigationalNutraceuticalWithdrawn

    Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn.

  4. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.

  5. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and...

  6. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier. … The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.

  7. Drug

    Phloxine B

    go.drugbank.com/drugs/DB13911
    ApprovedWithdrawn

    Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing

  8. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  9. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.

  10. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.